Xspray Pharma moves up to Nasdaq Stockholm’s Mid Cap-segment
17 december, 2020
Xspray Pharma (publ) (Nasdaq Stockholm: XSPRAY) announces today that the company’s share will be moved to Nasdaq Stockholms Mid Cap segment on 4 January 2021
The move from the Small Cap is a result of Nasdaq’s annual review of the average market values within the Nordic market segments. The Mid Cap segment includes companies with a share value between 150 million EUR and 1 billion EUR. The move was announced by Nasdaq Stockholm on 17 December 2020.
Xspray Pharma has been listed on Nasdaq First North Growth Market since 2017, and the company’s shares has been traded on Nasdaq Stockholm since March 27, 2020. The company will move from the Small Cap segment to the Mid Cap segment after a strong share price development during 2020.
For further information, please contact:
Per Andersson, CEO, Xspray Pharma ABPhone: +46 (0) 706 88 23 48E-mail: per.andersson@xspray.com
About Xspray Pharma
Xspray Pharma AB (publ) is a product development company with multiple product candidates in clinical development. Xspray uses its innovative, patented RightSize technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.
The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today’s original drugs before the secondary patents expire. Xspray’s goal is to become the leader in the development of improved drugs or generic versions of PKIs already marketed for the treatment of cancer, which numbered to 54 in December 2019. The company’s leading product candidates, HyNap-Dasa, HyNap-Sora and HyNap-Nilo, are stable amorphous versions of the three blockbuster cancer drugs Sprycel® (dasatinib), Nexavar® (sorafenib) and Tasigna® (nilotinib), respectively. The launch of the first product candidate, HyNap-Dasa, is planned to take place in 2021. The substance patent for the original drug Sprycel® (dasatinib) expires at the end of 2020, and the secondary patents in 2026, which offers Xspray’s HyNap-Dasa a period of five years of semi-exclusivity before other competitors gain access to the market.
The company has patented manufacturing technology, equipment and the resulting products. The shares in Xspray Pharma are traded on Nasdaq Stockholm.www.xspraypharma.com
Attachments
Xspray Pharma moves up to Nasdaq Stockholm’s Mid Cap-segment
Ämnen i artikeln
Xspray Pharma moves up to Nasdaq Stockholm’s Mid Cap-segment
17 december, 2020
Xspray Pharma (publ) (Nasdaq Stockholm: XSPRAY) announces today that the company’s share will be moved to Nasdaq Stockholms Mid Cap segment on 4 January 2021
The move from the Small Cap is a result of Nasdaq’s annual review of the average market values within the Nordic market segments. The Mid Cap segment includes companies with a share value between 150 million EUR and 1 billion EUR. The move was announced by Nasdaq Stockholm on 17 December 2020.
Xspray Pharma has been listed on Nasdaq First North Growth Market since 2017, and the company’s shares has been traded on Nasdaq Stockholm since March 27, 2020. The company will move from the Small Cap segment to the Mid Cap segment after a strong share price development during 2020.
For further information, please contact:
Per Andersson, CEO, Xspray Pharma ABPhone: +46 (0) 706 88 23 48E-mail: per.andersson@xspray.com
About Xspray Pharma
Xspray Pharma AB (publ) is a product development company with multiple product candidates in clinical development. Xspray uses its innovative, patented RightSize technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.
The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today’s original drugs before the secondary patents expire. Xspray’s goal is to become the leader in the development of improved drugs or generic versions of PKIs already marketed for the treatment of cancer, which numbered to 54 in December 2019. The company’s leading product candidates, HyNap-Dasa, HyNap-Sora and HyNap-Nilo, are stable amorphous versions of the three blockbuster cancer drugs Sprycel® (dasatinib), Nexavar® (sorafenib) and Tasigna® (nilotinib), respectively. The launch of the first product candidate, HyNap-Dasa, is planned to take place in 2021. The substance patent for the original drug Sprycel® (dasatinib) expires at the end of 2020, and the secondary patents in 2026, which offers Xspray’s HyNap-Dasa a period of five years of semi-exclusivity before other competitors gain access to the market.
The company has patented manufacturing technology, equipment and the resulting products. The shares in Xspray Pharma are traded on Nasdaq Stockholm.www.xspraypharma.com
Attachments
Xspray Pharma moves up to Nasdaq Stockholm’s Mid Cap-segment
Ämnen i artikeln
Fondernas placeringar
Placeras aktieanalyser
-992x558.png&w=3840&q=75)
Aktieråd
-160x160.jpg&w=3840&q=75)
Fondernas placeringar
Placeras aktieanalyser
Aktieråd
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
